Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

Toronto, Ontario--(Newsfile Corp. - June 13, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has granted 3,050,000 stock options (the "Options") to various directors, officers, employees and consultants of the Company. Each Option is exercisable at a price of $0.06 for one common share of the Company (each a "Common Share") for a period of five years from the date of grant and are being issued under the terms of the Company's Omnibus Long-Term Incentive Plan.

Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the first quarter ended March 31, 2025 ("Q1 2025). In Q1 2025, Glow delivered record revenue, sustained high gross margins, and achieved key balance sheet improvements, reflecting the Company's continued focus on delivering sustainable, profitable growth.

Toronto, Ontario--(Newsfile Corp. - May 1, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth quarter and the fiscal year ended December 31, 2024 ("Q4 2024" and "FY 2024"). In Q4 2024, Glow achieved record revenue, industry-leading gross margins, and key balance sheet improvements, reflecting the Company's commitment to delivering sustainable, profitable growth.

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif.

Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the appointment of David Côté as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Côté is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth.

Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has granted 3,650,000 stock options (the "Options") to various officers and consultants of the Company. Each Option is exercisable at a price of $0.06 for one common share of the Company (each a "Common Share") for a period of five years from the date of grant and are being issued under the terms of the Company's Omnibus Long-Term Incentive Plan.

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") announces that, further to its news release dated December 12, 2024, it has issued 10,000,000 common shares (the "Shares") at a deemed price of $0.20 per Share to Swiss PharmaCan AG (the "Seller") as the final payment (the "Share Payment") under the Share Exchange Agreement dated June 18, 2020, and amended as of December 12, 2024 (the "Amendment"), among the Seller, Swiss Pharma Corp. ("Swiss Pharma"), and the Company (the "Share Exchange Agreement") in connection with the Company's acquisition of all outstanding shares of Swiss Pharma. The Amendment reduced the total number of Shares issuable to the Seller under the Share Exchange Agreement from 30,000,000 to 15,000,000.

Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Glow Lifetech Corp. (CSE: GLOW) ("Glow" or the "Company") announces it plans to issue 10,000,000 Shares at a deemed price of $0.20 per Share to Swiss PharmaCan AG (the "Seller") as the final payment (the "Share Payment") under the Share Exchange Agreement (the "Share Exchange Agreement") dated June 18, 2020, and amended as of the date hereof (the "Amendment"), which was entered into among the Seller, Swiss Pharma Corp. ("Swiss Pharma"), and the Company in connection with the Company's acquisition of all outstanding shares of Swiss Pharma. The Amendment reduced the total number of Shares issuable to the Seller under the Share Exchange Agreement from 30,000,000 to 15,000,000.

Toronto, Ontario--(Newsfile Corp. - December 2, 2024) - Glow LifeTech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the third quarter ended September 30, 2024 ("Q3 2024"). In Q3 2024, the Glow achieved record revenue, robust gross margins, and key balance sheet improvements, reflecting the Company's commitment to delivering sustainable, profitable growth.